Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio

Shots:

• J&J entered into a definitive agreement to acquire Intra-Cellular Therapies, incl. its drugs Caplyta & ITI-1284, for a total equity value of ~14.6B (cash + debt), with shareholders receiving $132/share in cash, making the latter private
• In Dec 2024, the latter filed an sNDA to the US FDA for Caplyta as adj. therapy for MDD. In addition, 2 P-III trials showed improved depressive symptoms & favorable safety, with additional P-III trials for bipolar I mania underway
• Caplyta (oral, QD) modulates serotonin (5-HT2A) & Dopamine (D2) receptors to treat schizophrenia & bipolar depression while ITI-1284 is in P-II trials for the treatment of GAD & AD related psychosis & agitation

Ref: Johnson & Johnson | Image: Intra-Cellular Therapies

Related News: Johnson and Johnson to Acquire V-Wave, Expanding and Strengthening J&J MedTech Segment

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com